Conserved HBV and HCV sequences useful for gene silencing
View Patent ↗Conserved consensus sequences from known hepatitis B virus strains and known hepatitis C virus strains, which are useful in inhibiting the expression of the viruses in mammalian cells, are provided. These sequences are useful to silence the genes of HBV and HCV, thereby providing therapeutic utility against HBV and HCV viral infection in humans.
1. A method for inhibiting expression of a polynucleotide sequence of hepatitis B virus in an in vivo mammalian cell comprising administering to said cell a double-stranded RNA effector molecule selected from the group consisting of: 1) a molecule consisting of the sequence of SEQ ID NO: 58 hybridized to a molecule with the reverse complement sequence of SEQ ID NO: 58; 2) a molecule consisting of the sequence of SEQ ID NO: 59 hybridized to a molecule with the reverse complement of SEQ ID NO: 59; and 3) a combination of the molecules of (1) and (2); wherein U is substituted for T, and wherein each effector dsRNA optionally comprises a single-stranded nucleotide sequence linking the sequence of SEQ ID NO: 58 or SEQ ID NO: 59 to its respective reverse-complement sequence.
2. The method of claim 1 , wherein said at least two double-stranded RNA effector molecules are administered to the cell by providing at least one expression vector encoding the double-stranded RNA effector molecules.
3. The method of claim 1 , wherein the double-stranded RNA effector molecules are hairpin dsRNA molecules.
4. The method of claim 2 , wherein the expression vector comprises at least one promoter selected from the group consisting of a polymerase I promoter, a polymerase III promoter, a U6 promoter, an H1 promoter, a 7SK promoter, and a mitochondrial promoter, said promoter operably linked to a sequence encoding one or more of said double-stranded RNA effector molecules.
5. A composition for inhibiting expression of a polynucleotide sequence of hepatitis B virus in an in vivo mammalian cell comprising a double-stranded RNA effector molecule selected from the group consisting of: 1) a molecule consisting of the sequence of SEQ ID NO: 58 hybridized to a molecule with the reverse complement sequence of SEQ ID NO: 58; 2) a molecule consisting of the sequence of SEQ ID NO: 59 hybridized to a molecule with the reverse complement of SEQ ID NO: 59; and 3) a combination of the molecules of (1) and (2); wherein U is substituted for T, and wherein each effector dsRNA optionally comprises a single-stranded nucleotide sequence linking the sequence of SEQ ID NO: 58 or SEQ ID NO: 59 to its respective reverse-complement sequence.
6. The composition of claim 5 , comprising at least one expression vector encoding said at least two double-stranded RNA effector molecules.
7. The composition of claim 5 , wherein the double-stranded RNA effector molecules are hairpin dsRNA molecules.